A case of diffuse hepatic angiosarcoma diagnosed by FDG-PET

Abstract

A 76-year-old woman was admitted to our hospital with a 2-month history of increasing abdominal distension, leg edema, and dyspnea. The serum transaminase level was about twice the upper limit of normal. The CT showed no tumor. Fluorine-18 2-deoxy-2-fluoro-D-glucose (FDG)-positron emission tomography (PET) showed diffuse abnormal accumulation throughout the entire liver. She was diagnosed by histopathological examination as having hepatic angiosarcoma causing veno-occlusive disease (VOD). This is the first report of hepatic angiosarcoma with FDG-PET.

Hepatic FDG Uptake is not Associated with Hepatic Steatosis but with Visceral Fat Volume in Cancer Screening

“…Subjects with malignancy or known liver diseases which can affect hepatic FDG uptake (hepatitis [10], lymphoma [11] and hepatic angiosarcoma [12]) were excluded. Blood sampling was done to check aspartate arminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH).…”

Co‐registered positron emission tomography/computed tomography and gadolinium‐ethoxybenzyl‐diethylenetriamine pentaacetic acid magnetic resonance imaging features of multiple angiosarcoma of the liver

“…The sensitivity of PET scanning for diagnosing soft tissue and bone sarcomas ranges 83–93% and is greater for high‐ and intermediate‐grade sarcomas . To our knowledge, there were only a few reports of HAS detected by FDG‐PET and PET/CT . The present case is the first to use FDG‐PET and Gd‐EOB‐DTPA‐MRI for primary staging of HAS.…”

F18-FDG PET/CT Scanning in Angiosarcoma: Report of Two Cases

“…To our knowledge there are only a few reports about angiosarcomas at uncommon localizations (cardiac, hepatic and venous regions) detected by FDG PET and PET/CT (1,7,8,9,10) and the value of FDG PET in diagnosis and staging was well-defined in these studies. However, early detection of local and/or distant metastases is a challenging problem in high-risk patients and has an important role to predict the patients’ outcomes.…”

“…There are some studies that reported the use of FDG PET and PET/CT in angiosarcomas (hepatic, cardiac, venous and cutaneous angiosarcomas) in the literature (1,6,7,8,9,10,11). In this paper, we aimed to report the potential benefits of F18-FDG PET/CT imaging in two angiosarcoma patients.…”